NASDAQ:IDYA

IDEAYA Biosciences News Headlines

$18.79
-0.89 (-4.52 %)
(As of 05/5/2021 03:59 PM ET)
Add
Compare
Today's Range
$18.71
$19.65
50-Day Range
$17.76
$24.83
52-Week Range
$5.76
$24.92
Volume2,153 shs
Average Volume211,923 shs
Market Capitalization$618.30 million
P/E RatioN/A
Dividend YieldN/A
Beta2.11

Headlines

IDEAYA Biosciences (NASDAQ IDYA) News Headlines Today

SourceHeadline
$9.97 Million in Sales Expected for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) This Quarter$9.97 Million in Sales Expected for IDEAYA Biosciences, Inc. (NASDAQ:IDYA) This Quarter
americanbankingnews.com - May 5 at 5:26 AM
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $20.73IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Down to $20.73
americanbankingnews.com - May 4 at 12:48 PM
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expected to Announce Earnings of -$0.28 Per ShareIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Expected to Announce Earnings of -$0.28 Per Share
americanbankingnews.com - May 3 at 6:08 AM
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from AnalystsIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Consensus Rating of "Buy" from Analysts
americanbankingnews.com - April 30 at 12:48 PM
HC Wainwright Raises IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $35.00HC Wainwright Raises IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $35.00
americanbankingnews.com - April 26 at 9:00 AM
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $38.00 by Analysts at Roth CapitalIDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $38.00 by Analysts at Roth Capital
americanbankingnews.com - April 22 at 12:08 PM
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up  Following Analyst UpgradeIDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up Following Analyst Upgrade
americanbankingnews.com - April 19 at 10:32 AM
2 Biotech Start-Ups Are Searching for Cancer’s Hidden Weaknesses. What to Know.2 Biotech Start-Ups Are Searching for Cancer’s Hidden Weaknesses. What to Know.
finance.yahoo.com - April 18 at 11:33 PM
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $31.00 at Roth CapitalIDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $31.00 at Roth Capital
americanbankingnews.com - April 17 at 4:08 PM
IDEAYA Biosciences (NASDAQ:IDYA) PT Raised to $34.00IDEAYA Biosciences (NASDAQ:IDYA) PT Raised to $34.00
americanbankingnews.com - April 17 at 3:08 PM
 Analysts Expect IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Will Post Earnings of -$0.24 Per Share Analysts Expect IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Will Post Earnings of -$0.24 Per Share
americanbankingnews.com - April 17 at 3:58 AM
IDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal MelanomaIDEAYA Reports Darovasertib (IDE196) Monotherapy Overall Survival Data and Observes Early Partial Responses in Binimetinib Combination in Metastatic Uveal Melanoma
finance.yahoo.com - April 16 at 8:30 AM
IDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal MelanomaIDEAYA Announces Investor Day Webcast to Review Clinical Data from Phase 1/2 Trial of Darovasertib (IDE196) Monotherapy and Combination with Binimetinib in Metastatic Uveal Melanoma
finance.yahoo.com - April 15 at 7:15 PM
IDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid TumorsIDEAYA Announces Dosing of First Patient of MAT2A Inhibitor IDE397 in Phase 1 Clinical Trial Evaluating MTAP-Deletion Solid Tumors
finance.yahoo.com - April 15 at 9:13 AM
IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $17.76IDEAYA Biosciences (NASDAQ:IDYA) Shares Gap Up to $17.76
americanbankingnews.com - April 13 at 11:10 AM
IDEAYA Posts Better-Than-Feared Quarterly Loss, Sales Top EstimatesIDEAYA Posts Better-Than-Feared Quarterly Loss, Sales Top Estimates
finance.yahoo.com - March 23 at 1:09 PM
IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue EstimatesIDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss, Lags Revenue Estimates
finance.yahoo.com - March 23 at 8:08 AM
IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196IDEAYA Announces Presentations at AACR Annual Meeting 2021 for Synthetic Lethality Programs IDE397 and PARG, and Kinase Inhibitor IDE196
finance.yahoo.com - March 11 at 9:06 AM
IDEAYA to Participate in Upcoming March 2021 Investor Relations EventsIDEAYA to Participate in Upcoming March 2021 Investor Relations Events
finance.yahoo.com - March 9 at 8:34 AM
Announcing: IDEAYA Biosciences (NASDAQ:IDYA) Stock Increased An Energizing 178% In The Last YearAnnouncing: IDEAYA Biosciences (NASDAQ:IDYA) Stock Increased An Energizing 178% In The Last Year
finance.yahoo.com - February 15 at 9:55 AM
IDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical AffairsIDEAYA Announces IDE397 IND Clearance by U.S. FDA to Initiate Phase 1 and Appointment of Matthew Maurer, M.D., as Vice President, Head of Clinical Oncology and Medical Affairs
finance.yahoo.com - February 8 at 10:09 AM
IDEAYA to Participate in Upcoming February 2021 Investor Relations EventsIDEAYA to Participate in Upcoming February 2021 Investor Relations Events
finance.yahoo.com - February 1 at 9:46 AM
Spelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology IndustrySpelman College and IDEAYA Biosciences Announce Partnership for Professional Development of the Next Generation of Female African American Leaders in the Biotechnology Industry
finance.yahoo.com - January 19 at 3:39 PM
IDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDAIDEAYA Biosciences Announces Submission of IND Application for MAT2A Development Candidate IDE397 with the U.S. FDA
finance.yahoo.com - January 11 at 8:15 AM
IDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET InhibitorIDEAYA Biosciences Doses First Patient in a Phase 1 Combination Study of IDE196 and Crizotinib, a cMET Inhibitor
finance.yahoo.com - January 5 at 9:08 AM
IDEAYA Biosciences Announces Addition to NASDAQ Biotechnology IndexIDEAYA Biosciences Announces Addition to NASDAQ Biotechnology Index
finance.yahoo.com - December 14 at 8:32 AM
Is IDYA A Good Stock To Buy Now?Is IDYA A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 10:38 PM
IDEAYA Bio: New GSK Partnership, $3B In Potential Cash Milestones, And 2 Key Therapeutics Advancing Rapidly, 34% UpsideIDEAYA Bio: New GSK Partnership, $3B In Potential Cash Milestones, And 2 Key Therapeutics Advancing Rapidly, 34% Upside
seekingalpha.com - December 11 at 2:36 AM
IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2%IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2%
finance.yahoo.com - December 8 at 1:50 PM
Analysts Just Published A Bright New Outlook For IDEAYA Biosciences, Inc.s (NASDAQ:IDYA)Analysts Just Published A Bright New Outlook For IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA)
nasdaq.com - November 18 at 8:39 AM
Industry Analysts Just Upgraded Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts By 95%Industry Analysts Just Upgraded Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts By 95%
finance.yahoo.com - November 17 at 9:22 AM
IDEAYA Biosciences, Inc. Just Reported A Surprise Loss: Heres What Analysts Think Will Happen NextIDEAYA Biosciences, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next
nasdaq.com - November 15 at 1:43 PM
Results: IDEAYA Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New ForecastsResults: IDEAYA Biosciences, Inc. Delivered A Surprise Loss And Now Analysts Have New Forecasts
finance.yahoo.com - November 15 at 1:43 PM
IDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business UpdateIDEAYA Biosciences, Inc. Reports Third Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - November 12 at 10:07 AM
IDEAYA to Participate in Upcoming November 2020 Investor Relations EventsIDEAYA to Participate in Upcoming November 2020 Investor Relations Events
markets.businessinsider.com - November 2 at 8:02 AM
IDEAYA Biosciences Inc.IDEAYA Biosciences Inc.
barrons.com - October 28 at 4:15 PM
IDEAYA Biosciences, Inc. Common Stock (IDYA)IDEAYA Biosciences, Inc. Common Stock (IDYA)
nasdaq.com - October 22 at 7:11 PM
Ideaya inks research pact for Synthetic Lethal cancer platformIdeaya inks research pact for Synthetic Lethal cancer platform
seekingalpha.com - October 22 at 2:10 PM
IDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And PlatformIDEAYA Announces Partnership With The Broad Institute And Advancement Of Synthetic Lethality Programs And Platform
finance.yahoo.com - October 22 at 9:10 AM
IDEAYA Biosciences Inc Registered Shs OutperformIDEAYA Biosciences Inc Registered Shs Outperform
markets.businessinsider.com - October 9 at 8:39 AM
Why Ideaya Biosciences Is Trading Higher TodayWhy Ideaya Biosciences Is Trading Higher Today
benzinga.com - October 8 at 2:01 PM
IDEAYA to evaluate IDE196+Pfizers crizotinib combo in solid tumors harboring GNAQ/11 mutationsIDEAYA to evaluate IDE196+Pfizer's crizotinib combo in solid tumors harboring GNAQ/11 mutations
seekingalpha.com - September 24 at 7:50 AM
Ideaya and Pfizer to test doublet therapy in certain solid tumorsIdeaya and Pfizer to test doublet therapy in certain solid tumors
seekingalpha.com - September 24 at 7:50 AM
IDEAYA Expands Clinical Trial Collaboration, Supply Agreement With Pfizer - Quick FactsIDEAYA Expands Clinical Trial Collaboration, Supply Agreement With Pfizer - Quick Facts
nasdaq.com - September 24 at 7:50 AM
What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.s (NASDAQ:IDYA) Shares?What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares?
finance.yahoo.com - August 19 at 5:39 PM
What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares?What Kind Of Shareholders Hold The Majority In IDEAYA Biosciences, Inc.'s (NASDAQ:IDYA) Shares?
finance.yahoo.com - August 19 at 5:39 PM
IDEAYA Biosciences EPS misses by $2.83IDEAYA Biosciences EPS misses by $2.83
seekingalpha.com - August 12 at 8:42 AM
IDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business UpdateIDEAYA Biosciences, Inc. Reports Second Quarter 2020 Financial Results and Provides Business Update
finance.yahoo.com - August 12 at 8:42 AM
IDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue EstimatesIDEAYA Biosciences, Inc. (IDYA) Reports Q2 Loss, Misses Revenue Estimates
finance.yahoo.com - August 12 at 8:42 AM
Is a Surprise Coming for IDEAYA Biosciences (IDYA) This Earnings Season?Is a Surprise Coming for IDEAYA Biosciences (IDYA) This Earnings Season?
finance.yahoo.com - August 7 at 12:47 PM
This page was last updated on 5/5/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.